This year the Eindhoven iGEM team aims to improve the treatment of the auto-immune disease dermatomyositis. This will be done using a cell-based therapy to locally reduce inflammation. The relevant non-pathogenic auto antibody, anti-MDA5, is used as a biomarker to detect local flare-ups and binds to a cell surface-receptor. This synthetic receptor is based on the concept of Generalized Extracellular Molecular Sensor (GEMS) platform. Binding of the receptor leads to an intracellular signal which turns on the transcription the cytokine IL-10. Subsequently the cytokine is extracellularly secreted to reduce the inflammatory symptoms. Although currently the therapy is based on the treatment of dermatomyositis, the flexibility of the GEMS platform offers the possibility to create a novel treatment for a broad range of other auto-immune disease.